Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Keira Fines"'
Autor:
Sean H. Lim, Kim M. Linton, Graham P. Collins, Joke Dhondt, Joshua Caddy, Liz Rossiter, Karan Vadher, Keira Fines, Laura E. Rogers, Diana Fernando, Louise Stanton, Andrew J. Davies, Peter W. M. Johnson, Gareth Griffiths
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-14 (2018)
Abstract Background Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunoc
Externí odkaz:
https://doaj.org/article/aec02f5cc1384a15b0945013d6790d3f
Autor:
Michael Fisher, Megan Lawrence, Richard Fitzgerald, Saye Khoo, Laura Else, Andrew Owen, Keira Fines, Michael Jacobs, Thomas Jaki, Rebecca Crook, Christie Woods, Parys Hatchard, Kelly Byrne, Lauren Walker, Gareth Griffiths, Rajith K. R. Rajoli, Sean Ewings, Izabela Eberhart, Pavel Mozgunov, Rebecca Lyon, Colin Hale, Tom Fletcher, Helen Reynolds, Geoffrey Saunders, Henry Pertinez, Emmanuel Okenyi, Timothy Rowland, Lucy Johnson, Karen Martin, Alieu Amara, Sujan Dilly-Penchala, David G. Lalloo, Robert Waugh
Publikováno v:
Clinical Pharmacology and Therapeutics
CLINICAL PHARMACOLOGY & THERAPEUTICS
CLINICAL PHARMACOLOGY & THERAPEUTICS
Funder: Unitaid
Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID-19), but repurposed antivirals have n
Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID-19), but repurposed antivirals have n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54180ab1be1e7ed86daeaf2ab703b5a0
Autor:
Kim Mallard, William Greenhalf, Lauren Walker, Susannah Condie, Ellice Marwood, Michael Jacobs, Tom Fletcher, Gareth Griffiths, Geoffrey Saunders, Sean Ewings, Victoria Shaw, Richard Fitzgerald, Kerensa Thorne, Olana Tansley-Hancock, Andrew Owen, Lucy Johnson, Sara Yeats, David G. Lalloo, Wendy Painter, Helen Reynolds, Henry Pertinez, Thomas Jaki, Christie Woods, Keira Fines, Emma Wrixon, Colin Hale, Andrea Corkhill, Katie Bullock, Mike Radford, Emily R. Adams, Nichola Downs, Saye Khoo, Justin Chiong, Wayne Holman, Rebecca Lyon, Pavel Mozgunov, Marcin D Bula, Jennifer L Gibney
Publikováno v:
The Journal of antimicrobial chemotherapy
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. Methods We undertook a dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5576a4da8769d3c6064bde32dbfec8
https://eprints.soton.ac.uk/476394/
https://eprints.soton.ac.uk/476394/
Autor:
Robert Waugh, Rebecca Lyon, Timothy Rowland, Kelly Byrne, Rebecca Crook, Michael Fisher, Sean Ewings, Megan Lawrence, Sujan Dilly-Penchala, Henry Pertinez, Laura Else, Helen Reynolds, Thomas Jaki, Rajith K. R. Rajoli, Richard Fitzgerald, Andrew Owen, Pavel Mozgunov, Lauren Walker, Saye Khoo, Colin Hale, Parys Hatchard, Karen Martin, Keira Fines, Izabela Eberhart, Alieu Amara, Lucy Johnson, Gareth Griffiths, David G. Lalloo, Tom Fletcher, Geoffrey Saunders, Michael Jacobs, Christie Woods
Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe COVID-19, but repurposed antivirals have not been successful to date because of redundancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45390ead44d97cf5e76f07e2c7b49732
https://doi.org/10.1101/2021.09.10.21263376
https://doi.org/10.1101/2021.09.10.21263376
Autor:
Kerensa Thorne, Andrew Owen, Justin Chiong, Thomas Jaki, Michael Jacobs, Gareth Griffiths, Sara Yeats, Tom Fletcher, Keira Fines, Susannah Condie, Geoffrey Saunders, Kim Mallard, Colin Hale, Jennifer L Gibney, Mike Radford, Nichola Downs, Olana Tansley-Hancock, Pavel Mozgunov, Marcin D Bula, Andrea Corkhill, Katie Bullock, Wendy Painter, Christie Woods, Victoria Shaw, William Greenhalf, Lauren Walker, David G. Lalloo, Wayne Holman, Richard Fitzgerald, Rebecca Lyon, Lucy Johnson, Henry Pertinez, Ellice Marwood, Sean Ewings, Emma Wrixon, Saye Khoo, Emily R. Adams, Helen Reynolds
BackgroundAGILE is a phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection.MethodsWe undertook a dose-es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d711f718d23a69bca351a8f58d141333
https://doi.org/10.1101/2021.05.03.21256309
https://doi.org/10.1101/2021.05.03.21256309
Autor:
Heng Sheng Sow, Gareth Griffiths, Kerensa Thorne, Cherish Boxall, Joshua Northey, Adam Coleman, Graham P. Collins, Andrew J. Gentles, Katy Mercer, Patrick G. Medd, Pamela McKay, Keira Fines, Robert Lown, Christopher Wignall, Sean H. Lim, Lorna Nunn, Louise Stanton, Zoe J. Konn, Wendy Osborne, Kim Linton, Matthew J. J. Rose-Zerilli, Josh Caddy
Publikováno v:
Blood. 138:715-715
Background: CD27 antibody stimulation of T cells has been shown to activate and promote myeloid cell infiltration leading to enhanced antibody-dependent cellular phagocytosis (ADCP) by anti-CD20 in lymphoma preclinical models (Turaj et al Cancer Cell
Autor:
Peter Johnson, Sean H. Lim, Andrew Davies, Laura E. Rogers, Kim Linton, Joke Dhondt, Louise Stanton, Diana Fernando, Liz Rossiter, Keira Fines, Karan D Vadher, Graham P. Collins, Joshua Caddy, Gareth Griffiths
Publikováno v:
Lim, S H, Linton, K M, Collins, G P, Dhondt, J, Caddy, J, Rossiter, L, Vadher, K, Fines, K, Rogers, L E, Fernando, D, Stanton, L, Davies, A J, Johnson, P W M & Griffiths, G 2018, ' RIVA-a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies : study protocol for a randomized controlled trial ', Trials, vol. 19, no. 1 . https://doi.org/10.1186/s13063-018-2996-6
Trials
Trials, Vol 19, Iss 1, Pp 1-14 (2018)
Trials
Trials, Vol 19, Iss 1, Pp 1-14 (2018)
Background Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunochemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7b0fe4040a30d354a55d5e635a0f1b
https://doi.org/10.1186/s13063-018-2996-6
https://doi.org/10.1186/s13063-018-2996-6